23948sdkhjf
  • {{ window.visitor.corporateClient.name }}
    Företagslösning
    {{ window.visitor.ipAccess.corporateClient.name }}
    {{ window.visitor.corporateClient.name }}

  • Välkommen till vår företagslösning

    Här kan du administrera användarna i din företagslösning.

  • Välkommen till din prenumeration för Life Science Sweden.

  • Welcome to our Corporate client solution

    Your IP is registered with the company mentioned above and provides access to Life Science Sweden.

  • Click here to go to sign-up
Logga in eller skapa en prenumeration för att spara artiklar
Få tillgång till allt innehåll på Life Science Sweden
Ingen bindningstid eller kortinformation krävs
Prova Life Science Sweden nu
Gäller endast personlig prenumeration.
Kontakta oss för en företagslösning.
Annons
Annons
News in English

Positive outcome in phase III for Sanofi’s eczema treatment

The antibody amlitelimab shows positive Phase III data as a treatment for atopic dermatitis. France‑based Sanofi now plans to submit global regulatory applications before the end of the year.
Annons

Amlitelimab is a monoclonal antibody designed to block OX40‑ligand, a molecule that drives chronic inflammation in the skin.

The substance has now been evaluated in two Phase III studies. In one of the studies, all primary and key secondary endpoints were met at week 24 in patients with moderate‑to‑severe atopic dermatitis.

Annons Annons
BREAKING
{{ article.headline }}
0.078|